The effect of cancer-associated mutations on ligand binding and receptor function – A case for the 5-HT2C receptor
Authors:
Open Access
- 30 October 2024
- journal article
- research article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 985, 177081
Abstract
No abstract availableKeywords
Funding Information
- Oncode Institute
- China Scholarship Council (201906210052)
This publication has 53 references indexed in Scilit:
- Molecular insights into the regulation of constitutive activity by RNA editing of 5HT2C serotonin receptorsCell Reports, 2022
- G Protein‐Coupled receptors and heterotrimeric G proteins as cancer driversFEBS Letters, 2020
- 5-HT2C Receptor Structures Reveal the Structural Basis of GPCR PolypharmacologyCell, 2018
- A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatmentPsychopharmacology, 2017
- Up-regulation of cathepsin S expression by HSP90 and 5-HT7 receptor-dependent serotonin signaling correlates with triple negativity of human breast cancerBreast Cancer Research and Treatment, 2016
- A systematic review and meta‐analysis of prescribing practices of antidepressants in cancer patientsPsycho-Oncology, 2016
- Transient Mammalian Cell Transfection with Polyethylenimine (PEI)2013
- The competitive and noncompetitive antagonism of receptor-mediated drug actions in the presence of spare receptorsJournal of Pharmacological and Toxicological Methods, 1993
- Measurement of protein using bicinchoninic acidAnalytical Biochemistry, 1985
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973